Applied Genetic Technologies (NASDAQ:AGTC) issued its earnings results on Thursday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.41, MarketWatch Earnings reports. The company had revenue of $5.93 million for the quarter. Applied Genetic Technologies had a negative net margin of 61.04% and a negative return on equity of 18.77%.
Shares of NASDAQ:AGTC opened at $3.38 on Friday. The company has a market capitalization of $61.28 million, a P/E ratio of -2.86 and a beta of 2.76. Applied Genetic Technologies has a fifty-two week low of $2.26 and a fifty-two week high of $7.50.
Large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its position in shares of Applied Genetic Technologies by 11.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 817,584 shares of the biotechnology company’s stock valued at $5,968,000 after acquiring an additional 85,686 shares during the period. Renaissance Technologies LLC raised its position in shares of Applied Genetic Technologies by 11.5% in the 3rd quarter. Renaissance Technologies LLC now owns 707,500 shares of the biotechnology company’s stock valued at $5,165,000 after acquiring an additional 73,000 shares during the period. Wells Fargo & Company MN raised its position in shares of Applied Genetic Technologies by 9,001.3% in the 3rd quarter. Wells Fargo & Company MN now owns 215,610 shares of the biotechnology company’s stock valued at $1,574,000 after acquiring an additional 213,241 shares during the period. Finally, Vanguard Group Inc raised its holdings in Applied Genetic Technologies by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 494,618 shares of the biotechnology company’s stock worth $3,611,000 after buying an additional 5,300 shares during the period. Institutional investors and hedge funds own 44.24% of the company’s stock.
WARNING: This article was published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/4139500/applied-genetic-technologies-agtc-releases-quarterly-earnings-results-beats-estimates-by-0-41-eps.html.
Applied Genetic Technologies Company Profile
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.
See Also: Should You Consider an Index Fund?
Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.